| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Kezar Life Sciences, Inc. (KZR) has 10 insiders with recent SEC Form 4 filings, including 12 buys and 0 sells. KZR is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Other | 7.0K | $51.5K | - | |
| ? | 5.0K | $36.8K | - | |
| ? | 5.0K | $36.8K | - | |
| ? | 5.0K | $36.8K | - | |
| ? | 5.0K | $36.8K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Aug 9, 2019 | Fowler John Franklin | CEO | Buy | 1,250 | $5.11 | $6,388.53 | +0.2% | |
| Aug 9, 2019 | Economides Vassiliki | SVP, Strategy &External Aff. | Buy | 1,020 | $4.96 | $5,057.36 | +236.7% | |
| Aug 9, 2019 | Belsky Marc | CFO | Buy | 500 | $4.82 | $2,410.00 | +100.0% | |
| Jul 26, 2019 | Belsky Marc | CFO | Buy | 500 | $5.67 | $2,835.18 | +112.6% | |
| Jul 22, 2019 | Economides Vassiliki | SVP, Strategy &External Aff. | Buy | 431 | $5.82 | $2,508.72 | New | |
| May 30, 2019 | Economides Vassiliki | SVP, Strategy &External Aff. | Buy | 750 | $10.19 | $7,642.50 | +7.1% | |
| Jun 25, 2018 | Bay City Capital LLC | 10% Owner | Buy | 150,000 | $15.00 | $2,250,000.00 | +31.8% | |
| Jun 25, 2018 | Cormorant Asset Management, LP50 | 10% Owner | Buy | 250,000 | $15.00 | $3,750,000.00 | +18.9% | |
| Jun 25, 2018 | Morningside Venture Investments Ltd93 | 10% Owner | Buy | 250,000 | $15.00 | $3,750,000.00 | +12.1% | |
| Jun 25, 2018 | Berger Franklin M52 | Director | Buy | 50,000 | $15.00 | $750,000.00 | +9.7% |